Buscar
Mostrando ítems 1-10 de 20
Palbociclib-Induced Cellular Senescence Is Modulated by the mTOR Complex 1 and Autophagy
(Multidisciplinary Digital Publishing Institute (MDPI), 2024)
Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells
(Humana Press, 2019-05)
Glioblastoma multiforme is the most aggressive primary brain tumor. Current knowledge suggests that the growth and recurrence of these tumors are due in part to the therapy-resistant glioma stem cell subpopulation, which ...
Palbociclib-induced autophagy and senescence in gastric cancer cells
(2017)
Targeting cyclin D-CDK4/6 kinase complexes has recently been shown to increase the survival of breast cancer patients with estrogen receptor positive breast tumors. Based on these outcomes, CDK4/6 inhibitors are currently ...
Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry
(2023)
Background The addition of cyclin-dependent kinases inhibitors (CDKi) to endocrine therapy (ET) as the first- or second line treatment improves progression-free and overall survival (OS) in hormone receptor-positive, HER2 ...
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
(2018)
Background
To compare the efficacy and toxicity of the combination of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and nonsteroidal aromatase inhibitors (AI) versus AI alone as first-line therapy for patients with ...
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
(2018)
Background
To compare the efficacy and toxicity of the combination of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and nonsteroidal aromatase inhibitors (AI) versus AI alone as first-line therapy for patients with ...
Acción de protección con medidas cautelares en contra del Instituto Ecuatoriano de Seguridad Social y del Ministerio de Salud Pública por la no entrega de medicamento (Palbociclib)
(Guayaquil: Delegación Provincial del Guayas, 2021)